GYBYS(00874)

Search documents
白云山等成立广药二期股权基金 出资额15亿
Xin Lang Cai Jing· 2025-08-05 06:09
Group 1 - The establishment of Guangzhou Guangyao Phase II Fund Equity Investment Partnership (Limited Partnership) has been announced, with a total investment of 1.5 billion RMB [1] - The fund is managed by Guangzhou Guangyao Capital Private Fund Management Co., Ltd., focusing on private equity investment, investment management, and asset management activities [1] - Partners in the fund include Baiyunshan (600332) and Guangzhou Guangyao Capital Private Fund Management Co., Ltd. [1]
智通港股通占比异动统计|8月4日
智通财经网· 2025-08-04 00:41
Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2]. Group 1: Companies with Increased Holdings - Shandong Molong (00568) saw the largest increase in holdings, up by 7.40%, bringing its total to 61.14% [2]. - Changfei Fiber Optic Cable (06869) experienced a 3.04% increase, with a new holding percentage of 47.11% [2]. - Meizhong Jiahe (02453) had a 2.67% increase, resulting in a holding percentage of 27.92% [2]. - Over the last five trading days, Changfei Fiber Optic Cable (06869) led with a 14.30% increase, now at 47.11% [3]. - Yisou Technology (02550) followed with a 12.39% increase, reaching 58.26% [3]. Group 2: Companies with Decreased Holdings - Baiyunshan (00874) recorded the largest decrease in holdings, down by 0.86%, now at 60.69% [2]. - Huaneng International Power (00902) also decreased by 0.86%, with a holding percentage of 46.50% [2]. - Beijing Capital Machinery (00187) saw a reduction of 0.83%, bringing its total to 46.04% [2]. - In the last five trading days, Shandong Xinhua Pharmaceutical (00719) had the most significant decrease at 3.52%, now at 43.97% [3]. - Asymchem Laboratories (06855) decreased by 2.89%, with a holding percentage of 47.86% [3].
白云山(600332) - H股公告(证券变动月报表)

2025-08-01 09:15
FF301 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 (「上交所」)上市之A股 | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,405,890,949 | RMB | | 1 RMB | | 1,405,890,949 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 1,405,890,949 | RMB | | 1 RMB | | 1,405,890,949 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致:香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 (「本公司」) 呈交日期: 2025年8月1日 I ...
白云山(600332) - H股公告(董事会召开日期)

2025-08-01 09:15
廣州白雲山醫藥集團股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性或完 整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 董事會 董事會會議召開日期 廣州白雲山醫藥集團股份有限公司(「本公司」)董事會(「董事會」)茲通告謹定於2025年8月15日(星期 五)舉行董事會會議,藉以審議及批准本公司及其附屬公司截至2025年6月30日止六個月未經審計財 務業績及處理其他事項(如有)。 中國廣州,2025年8月1日 於本公告日,本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生,及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 ...
白云山(00874) - 董事会会议召开日期

2025-08-01 08:37
中國廣州,2025年8月1日 於本公告日,本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生,及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 廣州白雲山醫藥集團股份有限公司(「本公司」)董事會(「董事會」)茲通告謹定於2025年8月15日(星期 五)舉行董事會會議,藉以審議及批准本公司及其附屬公司截至2025年6月30日止六個月未經審計財 務業績及處理其他事項(如有)。 廣州白雲山醫藥集團股份有限公司 董事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性或完 整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 董事會會議召開日期 ...
白云山(00874) - 月报表

2025-08-01 08:32
FF301 致:香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 (「本公司」) 呈交日期: 2025年8月1日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00874 說明 香港聯交所上市 H 股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 219,900,000 RMB 1 RMB 219,900,000 增加 / 減少 (-) RMB 本月底結存 219,900,000 RMB 1 RMB 219,900,000 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 (「上交所」)上市之A股 | | | | | | | | 法定/ ...
中国生命科学趋势洞察
Sou Hu Cai Jing· 2025-07-31 19:01
Core Insights - The Chinese life sciences industry is undergoing rapid transformation driven by policy relaxation, technological innovation, the rise of domestic companies, and the development of specialized real estate ecosystems [9][18][39] - The report "Trends in China's Life Sciences" provides a comprehensive overview of current market dynamics, regulatory changes, and future development directions [9] Policy Environment - Nationally, China has relaxed foreign investment restrictions in gene and cell therapy, allowing foreign-owned hospitals in major cities [10][20] - Local governments in cities like Beijing, Shanghai, and Shenzhen are offering targeted subsidies and fast-track approval processes to support biotechnology development [10][27] Industry Innovation and Company Growth - Chinese life sciences companies are shifting from generic drug production to innovative therapies, with firms like CanSino Biologics and BeiGene leading in CAR-T cell therapy and bispecific antibodies [11][29] - These companies are attracting international investment and licensing agreements, enhancing China's position in the global life sciences sector [11][39] Real Estate Development and Regional Hubs - Innovation hubs such as Suzhou BioBay and Shanghai Zhangjiang Hi-Tech Park provide end-to-end support, including shared laboratories and GMP-compliant facilities [12][35] - Second-tier cities like Chengdu and Ningbo are emerging as new growth centers, expanding the life sciences ecosystem [12][35] Owner Perspective - Real estate developers are adapting to industry-specific needs through light-asset models and flexible leasing arrangements [14][45] - While first-tier cities face saturation, demand remains robust in central and western regions, with a focus on sustainability and compliance [14][45] Tenant Perspective - Life sciences tenants are responding to regulatory reforms and increased compliance requirements, seeking flexibility and proximity to talent and infrastructure [15][46] - The highest demand is for GMP-certified laboratories and modular production facilities, emphasizing location advantages and sustainability certifications [15][46] Future Outlook - Growth opportunities lie in AI-driven drug development, personalized medicine, and advanced therapies, supported by government policies [16][39] - Life sciences real estate is evolving from generic parks to specialized, digitally-enabled facilities with high compliance and flexibility [16][39]
港股异动 | 白云山(00874)涨近3% 近日拟与广药资本设立广药基金二期 加大医药健康产业孵化及投资力度
智通财经网· 2025-07-30 03:29
Core Viewpoint - Baiyunshan (00874) has seen a nearly 3% increase in stock price, currently at HKD 18.62, with a trading volume of HKD 62.93 million, following the announcement of a partnership agreement with Guangzhou Pharmaceutical Capital to establish the second phase of the Guangzhou Pharmaceutical Fund [1] Group 1: Company Actions - Baiyunshan announced a partnership agreement with Guangzhou Pharmaceutical Capital to invest RMB 1.4985 billion and RMB 1.5 million respectively in the establishment of the second phase of the Guangzhou Pharmaceutical Fund [1] - The company will have substantial control over the second phase of the Guangzhou Pharmaceutical Fund, and its financial performance will be included in the company's consolidated financial statements [1] Group 2: Investment Focus - The partnership aims to conduct equity investments in the biopharmaceutical sector through direct or indirect means to achieve investment returns [1] - The investment strategy will align with the company's strategic planning, focusing on sub-fund investments and direct project investments in pharmaceuticals, medical devices, and healthcare services within the biopharmaceutical and health sectors [1] Group 3: Strategic Goals - The establishment of the second phase of the Guangzhou Pharmaceutical Fund is intended to seize industry development opportunities and accelerate the company's layout in the biopharmaceutical health sector [1] - The initiative aims to enhance the company's efforts in incubating and investing in the pharmaceutical health industry [1]
避暑补水备药正当时,相关常用药“供需两旺”
Guang Zhou Ri Bao· 2025-07-27 13:19
Core Insights - Recent high temperatures have led to increased demand for summer health products, particularly heatstroke prevention and gastrointestinal medications [1] Offline Market Trends - Sales of heatstroke and gastrointestinal medications have surged, with some products seeing a nearly 50% month-on-month increase, such as Huoxiang Zhengqi Water [2] - Baiyunshan Banlangen Granules, a well-known product in the market, has experienced a sales peak, attributed to its recognized efficacy in preventing colds [2] Online Market Trends - Online platforms like Meituan have reported over 120% month-on-month growth in orders for heatstroke medications since July, with popular items including Huoxiang Zhengqi Oral Liquid and Shidizhu [3] - Meituan is actively promoting health initiatives during high-temperature periods, including free distribution of cooling medications to outdoor workers [3] Pharmacist Recommendations - Pharmacists advise that traditional Chinese medicine (TCM) should only be used for mild conditions and recommend consulting healthcare professionals before use [5] - Specific warnings are issued regarding the use of certain medications, such as Huoxiang Zhengqi Water and Shidizhu, which contain alcohol and are not suitable for certain populations [5]
广州白云山医药集团股份有限公司 关于子公司中期票据和超短期融资券获准注册的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-07-25 23:56
Group 1 - The company has approved the registration of medium-term notes and ultra-short-term financing bonds for its subsidiary, Guangzhou Pharmaceutical Co., Ltd., with a total amount of up to RMB 16 billion and RMB 20 billion respectively [1][2][3] - The registration for the medium-term notes is valid for two years and will be underwritten by China Merchants Bank [2] - The registration for the ultra-short-term financing bonds is also valid for two years and will be co-underwritten by China Merchants Bank and Industrial Bank [3] Group 2 - The company plans to invest RMB 14.985 billion as a limited partner in the establishment of the Guangzhou Traditional Chinese Medicine Fund Phase II, accounting for 99.90% of the total subscription amount [6][8] - The total scale of the fund is RMB 15 billion, with the management being handled by Guangzhou Traditional Chinese Medicine Capital Private Fund Management Co., Ltd., a subsidiary of the company's controlling shareholder [6][10] - The fund aims to invest in the biopharmaceutical sector, focusing on projects that align with the company's strategic development [16][25]